Travere Therapeutics, Inc. (TVTX) bonds
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Travere Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Travere Therapeutics's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Matures | Amount issued | Carrying value |
|---|---|---|---|---|
| Senior Notes Due 2029 Convertible at $32 a share | 2.25% | 2029 | – | $94.88M |
| Senior Notes Due 2029, Issued Pursuant to Underwriters Option | – | 2029 | – | $41.30M |
| Senior Notes Due 2032 Convertible at $65 a share | 0.50% | 2032 | $525.00M | $525.00M |
| Senior Notes Due 2032, Issued Pursuant To Underwriters Option | – | 2032 | $50.00M | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?